Lymphomas & Lymphoid Neoplasia

Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

Catherine Diefenbach: Polatuzumab Vedotin for Follicular Lymphoma

Dr. Diefenbach shares results from a phase Ib/II trial of polatuzumab vedotin plus obinutuzumab and lenalidomide for relapsed/refractory follicular lymphoma.

Is There a Role for AHCT Consolidation in MCL in the Rituximab Era?

The availability of rituximab-containing induction regimens for patients with mantle cell lymphoma (MCL) has improved outcomes, but younger, transplant-eligible patients may benefit from consolidative...

No Benefit in Adding Rituximab to MBVP in CNS Lymphoma

Results from a phase III trial suggest there is no survival benefit of adding the anti-CD20 monoclonal antibody rituximab to a standard methotrexate-based chemotherapy...

Japan Sets $306,000 Price for Tisagenlecleucel

The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel was approved for use in Japan in March 2019, and a government panel recently set the...

Medicare Payments for CAR T-Cell Therapy May Be on the Rise

Medicare beneficiaries with relapsed or refractory leukemia and lymphoma may soon have another treatment option. At least, that’s the hope of officials at the...
WIB_icon

Evaluating Thalidomide-Cyclophosphamide-Prednisone for Idiopathic Multicentric Castleman Disease

An oral combination of thalidomide, cyclophosphamide, and prednisone (TCP) induced durable tumor and symptomatic response rates in nearly half of patients with newly diagnosed...

Adolescent and Young Adult Cancer Survivors Face Higher Risk of Second Cancers

People who were diagnosed with cancer as adolescents or young adults (AYAs) have an excess risk of developing a subsequent primary neoplasm later in...
On location

Are CAR T-Cell Therapies Moving to Hodgkin Lymphoma?

Results from two studies presented at the 2019 Transplantation & Cellular Therapy Meetings suggest that Hodgkin lymphoma (HL) may be the next target for...
On location

Adoptive “Non-Engineered” T-Cell Therapy Shows Preliminary Efficacy in Lymphomas

Chimeric antigen receptor (CAR) T-cell therapies engineered to recognize and destroy CD19 antigens on the surface of lymphoma cells have revolutionized the treatment of...

Patient With HIV and Hodgkin Lymphoma Is Virus-Free Following Transplant

An allogeneic hematopoietic cell transplantation (alloHCT) intended to cure a patient’s refractory Hodgkin lymphoma (HL) may have also put his HIV virus into remission,...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.